Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H20N2O7 |
Molecular Weight | 388.3713 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C([C@H]1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)=O
InChI
InChIKey=NCUCGYYHUFIYNU-KRWDZBQOSA-N
InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3/t17-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8519282
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8519282
S-aranidipine or (S)-MPC-1304 is an enantiomer of MPC-1304 (methyl 2-oxopropyl 1,4-dihydro-2,6-di-methyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), a calcium entry blocker. The Ca2+ entry blocking activity of the (S) enantiomer of MPC-1304 was approximately 150 times greater than that of its (R) enantiomer. Likewise, the antihypertensive effect of the (S) enantiomer was twice as great as that of MPC-1304 (racemate) in conscious spontaneously hypertensive rats, while the (R) enantiomer was ineffective. Thus, most of the pharmacological activity of MPC-1304 resides in its (S) configuration.
Originator
Sources: Ohno, S., O. Komatsu, K. Mizukoshi, N. Akimatsu and N. Oda, 1991, Synthesis of metabolites of MPC-1304, a new calcium antagonist, and related compounds and optical resolution of MPC-1304 and related compounds, J. Pharmacobio-Dyn. 14, s-108
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8519282
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8519282 |
3.3 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8519282
0.1, 0.3 and 1 mg/kg p.o. (S)-MPC-1304 (S-aranidipine) showed marked hypotensive effects in conscious spontaneously hypertensive rats
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8519282
(S)-MPC-1304 (S-aranidipine) inhibits calcium-induced contractions in the isolated rabbit aorta with IC50 values of 3.3 nM
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25273590
Created by
admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
|
PRIMARY | |||
|
D594X9Z4OS
Created by
admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
|
PRIMARY | |||
|
148372-44-5
Created by
admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD